Silence Therapeutics plc Basic Shares Outstanding (Weighted Average)
Silence Therapeutics plc (SLNCF) reported Basic Shares Outstanding (Weighted Average) of 141.71 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-10
- Silence Therapeutics plc weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 141.71M shares, a 0.01% increase year-over-year.
- Silence Therapeutics plc weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 141.70M shares, a 0.02% increase year-over-year.
- Silence Therapeutics plc weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 141.70M shares, a 0.01% increase year-over-year.
- Silence Therapeutics plc weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 141.70M shares, a 0.36% increase year-over-year.
- Silence Therapeutics plc weighted average number of shares outstanding, basic for fiscal 2025 was 141.69M shares, a 2.12% increase from fiscal 2024.
- Silence Therapeutics plc weighted average number of shares outstanding, basic for fiscal 2024 was 138.75M shares, a 24.69% increase from fiscal 2023.
- Silence Therapeutics plc weighted average number of shares outstanding, basic for fiscal 2023 was 111.28M shares, a 15.21% increase from fiscal 2022.
- Silence Therapeutics plc weighted average number of shares outstanding, basic for fiscal 2022 was 96.58M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 141.71M shares 10-Q · filed 2026-08-10 | 141.71M shares 10-Q · filed 2026-08-10 | 141.70M shares derived: average of 3 quarters · filed 2026-08-10 | 141.70M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 141.70M shares 10-Q · filed 2026-05-07 | 141.70M shares derived: average of 2 quarters · filed 2026-05-07 | 141.70M shares derived: average of 3 quarters · filed 2026-05-07 | 141.70M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | 141.70M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 141.70M shares derived: average of 2 quarters · filed 2026-03-05 | 141.70M shares derived: average of 3 quarters · filed 2026-08-10 | 141.69M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 141.70M shares 10-Q · filed 2025-11-06 | 141.70M shares derived: average of 2 quarters · filed 2026-08-10 | 141.69M shares 10-Q · filed 2025-11-06 | 141.69M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | 141.70M shares 10-Q · filed 2026-08-10 | 141.69M shares 10-Q · filed 2026-08-10 | 141.69M shares derived: average of 3 quarters · filed 2026-08-10 | 141.56M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | 141.68M shares 10-Q · filed 2026-05-07 | 141.68M shares derived: average of 2 quarters · filed 2026-05-07 | 141.52M shares derived: average of 3 quarters · filed 2026-05-07 | 141.19M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 141.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 141.44M shares derived: average of 2 quarters · filed 2026-03-05 | 141.03M shares derived: average of 3 quarters · filed 2026-03-05 | 138.75M shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 141.20M shares 10-Q · filed 2025-11-06 | 140.70M shares derived: average of 2 quarters · filed 2025-11-06 | 137.78M shares 10-Q · filed 2025-11-06 | |
| 2024-06-30 | 140.21M shares 10-Q · filed 2025-08-07 | 136.05M shares 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 131.88M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 111.28M shares 10-K · filed 2025-02-27 | |||
| 2022-12-31 | 96.58M shares 10-K · filed 2025-02-27 |